WeedLife News Network

Hot off the press cannabis, marijuana, cbd and hemp news from around the world on the WeedLife Social Network.

Michigan marijuana recall reversal let businesses sell contaminated cannabis

More than 500 ounces of potentially contaminated marijuana — including some that tested positive for a fungus that can lead to lung infections or death — was quietly returned to store shelves in Michigan late last year, an MLive investigation revealed.

The action was the latest in a chain of events set in motion by a November 2021 recall of nearly 64,000 pounds of marijuana deemed potentially unsafe by the state’s Marijuana Regulatory Agency (MRA).
 
The recall was prompted by a lack of faith in results from Viridis, a Michigan-based laboratory with two locations. Retests following the recall found some of cannabis contained higher than allowable levels of yeast and mold, and in some cases, the potentially dangerous banned pathogenic fungus, aspergillus, which can cause lung infections leading to death.
 
However, when a state judge reversed parts of the recall, state regulators said they had few options but to release the marijuana that failed retesting for possible sale. In fact, emails obtained by MLive via the Freedom of Information Act, show at least nine growers or retailers pressured the state to release their product from holds, despite the fact that it failed retesting.
 
MRA spokesman David Harns told MLive on Jan. 13 that nearly 32 pounds -- that’s 513 ounces of marijuana -- failed safety testing, yet made it to store shelves with no clear indicator on packaging notifying customers of potential danger.
 
“This product has been sold” or “is currently available for sale,” Harns said.
 
There were 2,475 other individual products -- items not sold as loose flower, potentially pre-rolled joints -- that also failed testing and were cleared for sale.
 
Harns said the figure doesn’t include an additional unidentified amount of failed marijuana remaining at processing or grow facilities that had yet to ship to retail stores.
 
Emails obtained by MLive reveal some companies pushed for the right to sell contaminated weed.
 
In emails sent to the MRA, two representatives from Divine Budz, identified as Samer Yokhana and Amanda Janowski, asked for clearance of marijuana that tested positive for aspergillus, considered to be one of the most dangerous contaminates the state looks for.
 
Aspergillus has potential to cause Aspergillosis, a lung infection that can be fatal. While there are threshold limits in marijuana for the presence of general molds and yeast, detection of any aspergillus automatically disqualifies it for sale.
 
In a Dec. 10 email, MRA Laboratory Specialist Dr. Patrice R. Fields notified Yokhana that some of the marijuana he and Janowski sought clearance for tested positive for aspergillus. In response, Yokhana asked Price to “look at the original testing,” indicating that despite failed retesting the marijuana met safety standards prior to the recall.
 
The MRA’s recall pertained to any marijuana flower tested by Viridis Laboratories, which operates labs in Lansing and Bay City. An audit of samples that passed testing from the Viridis Lansing lab were later tested and found to contain aspergillus. But on Dec. 3, Court of Claims Judge Christopher Murray overturned part of the recall, saying since the audit only pertained to the Lansing lab, the recall for product tested in Bay City wasn’t justified.
 
“Our product was 100% tested at the Viridis North location (in Bay City),” Yokhana said in an email to the MRA. “I understand what you are saying, but the judge’s order for a (temporary restraining order on the recall for marijuana tested in Bay City) is for everything to return to status quo before this happened, which means this failed testing needs to return to its original form …
 
“This has and is costing us (an extensive) amount of losses.”
 
Samer Yokhana is named in state licensing records as a supplemental applicant, meaning he is a manager or partial owner, of two marijuana grows, including Vasmed in Vassar and Elite Pharms in Bloomfield Hills. Divine Budz is a marijuana brand with an active Facebook page listing Yokhana’s email address in the contact information.
 
MLive called a phone number associated with Divine Budz that was answered by a woman who identified herself as “Amanda.” The woman promptly hung up when the reporter identified himself. She did not answer when the number was called back.
 
Hours later, a man who identified himself as Yokhana, returned a call and said his company’s marijuana “didn’t fail for aspergillus. They just did a recall for Viridis labs.”
 
When asked specifically about the emails sent to the MRA, Yokhana said a manager would contact MLive with more information, but no one ever did.
 
Thaier Fandakly, who identified himself in an email with state officials as a technology manager representing Mediq Laboratories, a Linwood-based grow facility, became so frustrated with the MRA’s failure to clear failed marijuana, that he complained in emails sent directly to Gov. Gretchen Whitmer and Attorney General Dana Nessel on Dec. 15.
 
“According to Judge Murray’s order on (Dec. 3), all recalled products should be treated as if (the) recall never happened,” Fandakly wrote. “I’m requesting our products be changed to ‘test passed’ immediately.
 
“This is costing our business irreparable harm each day (the) MRA delays the reversal. Additionally, this is upsetting our vendors that we have worked hard to keep a good standing relationship with.”
 
MLive sent several messages to the email address in MRA records for Mediq Laboratories, and received no response. In a phone call to a number linked to Fandakly, a man who identified himself as a former coworker said he contacted Fandakly, who did not wish to comment.
 
Six of the companies initiating emails reviewed by MLive, including MNS Stephens Ventures in Warren, Custom Genetics in Whittemore, Aunt Sparkies in Vassar, Levels Cannabis in Center Line, Goldkine Cannabis in Warren and High Mountain Cannabis Company in Vassar, never responded to requests for comment via phone or email contact.
 
Three businesses, Mediq Laboratories in Linwood, Puff Cannabis in Madison Heights and Divine Budz in Sterling Heights, said they didn’t wish to discuss the emails when contacted by phone.
 
Three other companies with emails included in the MRA records release -- Green Mitten Pharms in Bentley, Wanda Products in Luzerne and Golden Harvests in Bay City -- said by phone or email their marijuana was never sold to customers or never failed testing but was on hold awaiting retesting. When the recall was lifted, the samples no longer required retesting and the businesses asked MRA to remove the holds.
 
David Pleitner, the CEO of Golden Harvests, in an email to MLive, said one of 28 samples failed retesting.
 
“It should be noted, this product passed its original test and passed one of two retests meaning two out of the three results passed full compliance,” he said. “However, out of an abundance of caution, we took immediate action with our retail partners and the product was either returned to us for remediation or destroyed.”
 
Joshua Smith, a cofounder of Green Mitten Pharms, when contacted by phone said his company’s marijuana never failed testing but was scheduled for retesting, which resulted in the MRA placing a hold on the product.
 
Emails from Jeff Tenniswood, who’s listed in state records as an owner of Troy-based Wanda Products, were included in the MRA records release, but Tenniswood said in a call with MLive his company’s marijuana never failed safety testing. It was placed on hold due to the recall and scheduled to be retested when the judge reversed the portion of the recall encompassing his product.
 
At that point, Tenniswood told MLive the business didn’t feel retesting was necessary, since it originally passed safety compliance requirements at the Viridis Bay City lab that was no longer part of the recall.
 
“The whole reason for having a regulated market” is to ensure product safety, Tenniswood said. “If it failed, then absolutely, it needs to be remediated for secondary testing. For us, that wasn’t the case. For us, our stuff never failed.”
 
Attorneys for the MRA filed a court motion asking the Court of Claims to reconsider the ruling, but it was denied and the MRA did not appeal.
 
The MRA did not notify the public specifically what products failed testing, as it has for past recalls, but did release a list of nearly 400 retailers that possessed recalled product.
 
The agency opened at least 22 investigations related to health complaints blamed on recalled marijuana that included reports of flu-like symptoms, nausea, headaches, asthmatic reactions and a case abdominal pain that resulted in pancreatitis and hospitalization.
 
“Each and every action the MRA took regarding this product safety recall was based solely on protecting Michigan’s cannabis consumers,” MRA spokesman David Harns said. “When we were taken to court in an effort to stop the recall, we raised concerns through our court pleadings about potential health and safety concerns. When a large portion of subsequent tests failed, we made sure that the court was aware.
 
“The MRA was enjoined by court order from taking any further action on the marijuana product that was carved out of the recall, even after filing a motion for reconsideration. The dedicated public servants at the MRA remain committed to keeping the safety of Michigan’s cannabis consumers as our primary focus as we work to establish Michigan as the national model for a regulatory program that stimulates business growth while preserving safe consumer access to marijuana.”
 
In its motion for reconsideration, the MRA said 26% of retested marijuana from the Bay City Viridis lab failed, according to court documents.
 
That doesn’t necessarily mean Viridis tests were flawed, and the company maintains its testing methods are and were accurate.
 
“The failed retests have no bearing on the accuracy of our initial laboratory results,” Viridis Laboratories CEO Greg Michaud said in December. “Once a sample has cleared point-in-time testing, the associated product goes through a variety of uncontrolled environments from transportation to processing/packaging, and finally to the provisioning centers where the product is handled by staff and customers. Contamination can and does occur at any part of these handling processes.”
 
In a comment for this story, Michaud said: “MRA rules currently do not require or even allow cannabis testing beyond the point-in-time testing. If the MRA believes that post-testing microbial growth is a health and safety issue, they should require re-testing of product if it’s still on shelves after a certain time has passed since the initial test.”
 
Viridis has conducted free retesting for thousands of samples to help ensure product safety since the “ill-advised and unnecessary recall,” Michaud said.
 
If customers attempt to purchase product that was originally tested and passed by the Viridis Bay City lab, the labeling will not indicate it failed retesting.
 
Retailers face a similar lack of transparency.
 
If we had the recalled marijuana “and it was sitting here on hold, if the flower producer sent it to be retested, and the judge lifted (the recall), we wouldn’t know that it got retested and failed during that period in time,” said Troy Boquette, the general manager of Freddie’s Joint, a retailer in Clio.
 
According to the MRA, product that failed safety testing would appear as such in the statewide system.
 
Freddie’s Joint was not among the companies that emailed the MRA to have product cleared, but like most retail locations in the state, did have in its inventory marijuana impacted by the recall.
 
“I don’t like the courts being the scientists and determining what’s safe and what’s not,” Boquette said. “I mean, it’s really black and white to me.
 
“It’s either safe or it’s not, and if the state of Michigan or a licensed testing facility says that it’s not safe, then it’s not safe to me, so I think anybody who would sell it is -- just, I’d question their motive.”
 
Rate this article: 
Select ratingGive Michigan marijuana recall reversal let businesses sell contaminated cannabis 1/5Give Michigan marijuana recall reversal let businesses sell contaminated cannabis 2/5Give Michigan marijuana recall reversal let businesses sell contaminated cannabis 3/5Give Michigan marijuana recall reversal let businesses sell contaminated cannabis 4/5Give Michigan marijuana recall reversal let businesses sell contaminated cannabis 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

Patent trolls beware! This lawyer is tracking every application in the psychedelics space

 

“So, DMT vapes have now been patented,” Graham Pechenik, a San Francisco-based registered patent attorney, tweeted earlier this month.

Only it wasn’t a celebratory tweet. The application was filed in July 2020, and although vaping DMT, a hallucinogenic tryptamine drug, has been around for more than 10 years, the patent was granted earlier this month. A simple Google search could have revealed that, argues Pechenik.

“This is how patent trolls function,” Pechenik tells The GrowthOp’s Sam Riches following his Twitter post that sparked online outrage.

Graham Pechenik is a registered patent attorney and the founder of Calyx Law. Photo provided.

e-mail icon
Continue reading

Can the Psychedelic Therapeutics Market Take Over Cannabis?

Psychedelics may find a smoother path toward federal legalization than cannabis has.

In this segment from Backstage Pass, recorded on Feb. 4, Motley Fool contributor Rachel Warren speaks with Tim Schlidt, co-founder and partner at psychedelic investment fund Palo Santo, about his work to help increase the supply of clinically effective and accessible mental health and addiction treatment solutions. Schlidt explains why he believes the pathway to federal legalization for psychedelics is much clearer than the approach cannabis is taking, for a multitude of reasons.

Rachel Warren: Psychedelic therapeutics, they are starting to gain broader recognition in the mainstream medical community. But at the same time, these treatments are still viewed by many with caution given their potential for abuse and even long-term negative outcomes in some cases. On the other hand, as we've been discussing, Wall Street seems to really be quite bullish about this space. This reminds me in some ways of how many investors have approached cannabis industry, which also as you mentioned faces a quasi legal landscape. I'm curious, do you think that the psychedelic therapeutics market could eventually outpace that of the cannabis market?

Tim Schlidt: I'm hesitant to say, it depends on how we define out pace, of course. I think from a market sizing standpoint, if cannabis could replace alcohol, the market potential there is very, very large. I will concede that point. Where I think this could certainly outpace cannabis is again from a regulatory perspective. I think the pathway to federal legalization is much, much better than the approach cannabis is taking for a multitude of reasons. That FDA pathway to DEA rescheduling I think is very superior. I forgot to mention earlier, we've seen a lot of case studies where this has occurred previously, be it Epidiolex, Marinol, Syndros, Xyrem, there's a lot of now-prescribed medications that were scheduled and got rescheduled upon FDA approval.

Also cannabis, even if you do achieve federal legalization, it's gone by such a state-by-state pathway that I think states are going to be hesitant to give up their tax revenue around cannabis. You're going to see this whole messy patchwork of state regulations versus federal regulations that you're just not dealing with that nearly as much here. It's a lot cleaner as a pathway. They will certainly outpace cannabis I think in terms of their timeline to market. We're seeing that already with maps advancing MDMA for PTSD, that will likely hit the market in 2023. Compass Pathways with psilocybin for treatment of resistant depression likely 2025 that that hits the market. It's within the next few years we could see psychedelics being prescribed for medical applications.

One other comment I'll make, just your comment on potential for abuse. I actually think psychedelics are much better than many known medications that are prescribed. Even we now know cannabis, there is some physical dependency around cannabis. With psychedelics, there's no physical dependency, at least for the classic psychedelics like an LSD, a mescaline, a psilocybin, since these are much more serotonin-based rather than dopamine-based, you don't really induce addictive behavior. Usually, any medications that activate your reward system, which is largely dopamine receptors and operating on those neurons, that's where you tend to see more abuse potential. We also know opioids as well, very potent opioid receptors.

e-mail icon
Continue reading

How Is cannabis helping so many people with post COVID-19 recovery?

New studies are showing how cannabinoids are helping patients with post-COVID recovery.

COVID-19 has taken countless lives worldwide, but thankfully with the vaccine, many have also been able to survive it.

However, surviving COVID-19 is not an easy feat. In many cases, the dreaded virus leaves damage in the bodies which we can feel for far long after we have tested negative. There are the usual symptoms such as dry cough, fever, colds, and shortness of breath.

The duration and severity of symptoms differs from one person to another, but there are also some people who will experience symptoms that will linger for a longer period of time. Depending on the case, the fatigue, shortness of breath, difficulty breathing, chest pains, stomach pains, brain fog, muscle pain, headaches, and heart palpitations among others.

When the symptoms persist for as long as 12 weeks after the infection, this is known as long COVID, and these conditions are not yet well understood. Doctors and researchers don’t know why it happens, who it will happen to, and how to prevent it. Of course, getting your vaccine helps reduce any complications, and a booster shot even if you have gotten COVID will also help. There is not much we can do to help treat it other than rest as much as you can, and for as long as it takes. Additionally, seeing your doctor to check for any complications will also help.

These can prevent us from going back to a normal, healthy life.
 

But what else can we do?

How Cannabis Can Aid In COVID Recovery

e-mail icon
Continue reading

Is Medical Marijuana Tax Deductible? IRS Official Provides 'More Clarity' After Misstatement

As we all know, the marijuana industry has grown substantially in recent years, with sales expected to hit $25 billion by 2025.

Revenue growth has been driven by more and more states legalizing the plant. In states like Illinois, cannabis sales pulled in nearly $1.4 billion in 2021,  exceeding liquor taxes by nearly $100 million over the same period, after outpacing it for the first time in February. (article originally appeared on Benzinga)

However, with the plant still illegal under federal law  – something that might change when/if Senate Majority Leader Chuck Schumer (D-N.Y.) and his colleagues file the long-awaited bill this April – conflict and ambiguity regarding the tax policy persist, creating "significant problems" for IRS and financial regulators, not to mention cannabis operators and companies.

With tax season upon us, confusion over whether medical marijuana is tax-deductible has come up, writes Marijuana Moment.

In an interview with C-SPAN's Washington Journal, IRS taxpayer advocate Erin Collins was asked by a caller from Nevada, where cannabis is fully legal, why he couldn't find an option on TurboTax to deduct his cannabis purchases!

Collins, appointed during the Trump administration, said she'd have to "plead ignorance on the marijuana" question "unless you're saying it's a medical deduction.

e-mail icon
Continue reading

Should Hospitals Allow Cannabis for the Terminally Ill?

Should terminal patients be able to get cannabis while at the hospital or hospice?

Even in states where cannabis has been legalized for medical use, patients struggle to find the information that they need when it comes to using cannabis as medicine.

There’s tons of questions that overwhelm patients: how much cannabis to use, what method of administration is best, how often to take it, and so much more. Given these circumstances, most patients are left to their own devices when it comes to deciding how to use cannabis. And even then, doctors still don’t feel that they are equipped with the right knowledge to prescribe cannabis as a medication or part of their therapy.

Having said that, we are severely limiting the impact cannabis could have on the lives of patients, especially those who are terminally ill. There is already an astounding body of evidence that cannabis can make life more manageable for those with cancer, struggling through chemotherapy and radiation, Parkinson’s Disease, and so much more.

So why can’t patients be given cannabis medications in the hospital, supervised the way they are with conventional medications?

California Is A Pioneer

In December 2021, California Governor Gavin Newsom made waves by signing a legislation from Senator Ben Hueso that would offer more choices for end-of-life options for locals with the requirement that certain healthcare facilities and hospitals would allow terminally-ill patients to use medical marijuana for pain relief or as part of their treatment.

e-mail icon
Continue reading

Medical Marijuana In Hawaii Still Conflicts With Federal Law

The Legislature can and should end this harmful discrimination against qualified patients and dispensaries.

It is curious to see the recent dispensary complaints about restrictive regulation and unsustainable tax burdens.

What is missing from this discussion is the fact that Hawaii’s eight dispensaries — as well as our 34,000 lawfully registered medical cannabis patients, for that matter — are all technically federal criminals because the mere possession of cannabis without formal authorization from the Drug Enforcement Administration is a violation of federal law and the federal regulation of marijuana.

The problems that the dispensaries are describing are almost entirely due to the consequences of being continuing criminal enterprises and drug traffickers in the eyes of the federal government, which prohibits the dispensaries from utilizing regular banking services or deducting standard business expenses from their federal tax returns, resulting in an exorbitant federal tax burden of about 70% that must be paid in cash.

This should make us all wonder why the dispensaries are not screaming bloody murder to do something about ending the 22-year-old conflict between the state-authorized medical use of cannabis and the federal regulation of marijuana.

Licensed medical cannabis dispensaries are well established in the islands. But patient and dispensary rights are at risk. Anthony Quintano/Civil Beat/2017


Continue reading

Cannabis-based epilepsy medicine Epidyolex approved for use on Scottish NHS

 

Scottish epilepsy patients as young as two could be given new cannabis-based medication today approved for use on the NHS.

Health bosses have given the green light to Epidyolex, which can help treat the symptoms of a rare genetic disease affecting around one in 10,000 people.

Tuberous sclerosis complex (TSC) causes tumours to grow in the body and around 80% of patients develop epilepsy from it, typically in their first year of life.

Additionally, for the majority of people, their condition doesn’t respond to standard anti-seizure medication – making today’s Scottish Medical Consortium decision a potential game-changer.

Scotland has become the second UK nation to approve the oral solution for use, following Wales.

Medication ‘desperately needed’ for families

Louise Fish, the chief executive of the Tuberous Sclerosis Association, says life could now be very different for those with the debilitating condition.

Graphic which represents brain damage
Continue reading

Long-Term Cannabis Smoking Appears to Alter Lung Function, But Not Like Tobacco

A long-term study tracking just over a thousand participants has found regular cannabis smoking can change the function of your lungs as you age. Unlike smoking a cigarette, however, cannabis seems to impact a person's breathing in a slightly different way. 

Over adulthood, tobacco smoking is associated with a progressive decline in how much air you can force from your lungs in a given amount of time. In comparison, cannabis smoking in the current study was connected to higher lung volumes in total.

Ultimately, the authors found both changes lead to similar end results – constricting airways and leading to hyperinflation and gas trapping.

These patterns of lung function match previous results from the same cohort, which were collected 13 years earlier when the participants were 32 years of age.

"Although the effects of cannabis were detrimental, the pattern of lung function changes was not the same," says respiratory specialist Bob Hancox from the University of Otago in New Zealand.

"The research found that prolonged cannabis use led to over-inflated lungs and increased the resistance to airflow to a greater extent than tobacco."

e-mail icon
Continue reading

Researchers find association with cannabis and cataracts

Cannabis consumers who had used the drug 11 to 100 times or more were four to five years younger “when they developed cataracts than subjects who never used cannabis.”

Researchers were not surprised by their recent findings, but argue added study is needed to determine if cannabis smoking, like cigarette smoking, is a risk factor for developing cataracts.

“Like tobacco smoke, cannabis smoke contains thousands of organic and inorganic chemical compounds,” U.S. investigators write in the study, published on Jan. 31 in the Journal Français d’Ophtalmologie.

According to the American Academy of Ophthalmology, cataracts affect more than 24.4 million people in the U.S. 40 and older, and about half of those by age 75. Clouding of the eye’s normally clear lens “can make it more difficult to read, drive a car (especially at night) or see the expression on a friend’s face,” the Mayo Clinic reports. With time, “cataracts will eventually interfere with your vision.”

In the new study, the authors point out that cannabis tar is chemically similar to tobacco smoke tar. That, coupled with the fact that more than 50 known carcinogens have been identified in cannabis tar, means “the association of cannabis with cataracts that we report here is not entirely surprising.”

To get a firmer grasp of the association, if any, researchers at the Icahn School of Medicine at Mount Sinai and at Severn Health Solutions analyzed data from the U.K. Biobank, a large-scale biomedical database and research resource, containing genetic and health information from half a million U.K. participants.

All subjects had cataracts and their tobacco/cannabis habits were known. Those who had ever smoked cannabis were included as part of the study group.

e-mail icon
Continue reading

Despite health risks, the use of this sleeping aid has increased over the years

Even though melatonin is an over-the-counter medicine, not enough is known about it for people to be consuming it so comfortably.

Sleep disorders are incredibly common, affecting about 70 million Americans a year. Medications and other substances that treat sleep are increasingly common, although with some concerning side effects that might impact sleep in the long term.

One of the most harmless solutions to this is melatonin, a compound that’s been growing in popularity over the years. Still, when used at high levels, it has a certain amount of risks.

According to a new study, melatonin use has increased over the past few years, increasing by more than twice the amount consumed a decade ago.

The study, published in JAMA Network, argues that even though melatonin is an over-the-counter medicine, not enough is known about it for people to be consuming it so comfortably. Despite the fact that people view it as a natural herb, the reality is that melatonin is a hormone. The consumption of it is so widespread that companies advertising it as a sleep aid vary wildly in the amount of melatonin per gram, at times providing more than the standard 5mg a day dosage that’s recommended for providing quick relief in sleep problems.

According to the NIH, melatonin has been linked with headaches, dizziness, nausea, irritability, anxiety and depression, and is capable of interacting with other medications. “We cannot be certain of the purity of melatonin that is available over the counter,” sleep specialist Rebecca Robbins told CNN.

While it appears that in the short term melatonin provides useful benefits, its long-term use is much more complex than a harmless pill that can put you to bed.

e-mail icon
Continue reading

The exploding health benefits of CBD + adaptogens

The benefits of CBD as well as adaptogens clearly fill a massive void in western medicine so it’s not surprising to see patients fall for their charms.

Cannabidiol (CBD) may seem like it’s been a hot topic on the wellness front for quite some time now. After all, the non-psychoactive compound of marijuana has touted for its stress and anxiety-relieving properties without getting you high. It has a cult following, and for good reason — there’s a lot of data and evidence that CBD does work. It’s everywhere these days, from CBD capsules to oils, beverages and edibles, getting rid of stress has never been easier.

But sharing the limelight with CBD these days are adaptogens.

Adaptogens have been known for hundreds of years, especially in Asia and India, and among those who follow Ayurvedic lifestyle principles. They refer to types of plants that possess special properties to help the body cope with stress, regulate healthy functioning and hormonal balance. Aside from that, they have numerous other health benefits such as help fighting off fatigue, reduce inflammation, improve sleep, and improve cognitive function even when we are under periods of stress among others.

Benefits of Combining CBD and Adaptogens

Popular and common adaptogens that you’ll easily encounter in the market are the following:

Ashwagandha: Widely used for centuries to treat stress and anxiety, and its use in ayurvedic potions. Ashwagandha is a root that is also used in some eastern delicacies.

e-mail icon
Continue reading

Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’

Women who smoke cannabis during pregnancy double the risk of stunting their baby’s growth, a study warns.

Risks of premature birth, lower birth weight and possible low intelligence in later life were all increased. The report came from data on 60,000 mothers in the US, Canada and Jamaica in 16 studies. Chances of newborns being small for their age rose by 61 per cent for cannabis users. And the risk of being born premature went up by 28 per cent. Scores given to newborns that assess pulse, breathing and reactions also fell by 26 per cent, the Marchand Institute for Minimally Invasive Surgery, US, found. Dr Greg Marchand said: “Women exposed to marijuana in pregnancy were at a significantly increased risk of adverse neonatal outcomes.

“Given increasing marijuana legalisation and use worldwide, raising awareness and educating patients about these adverse outcomes may help to improve neonatal health.”

Rate this article: 
Select ratingGive Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’ 1/5Give Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’ 2/5Give Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’ 3/5Give Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’ 4/5Give Mums-to-be who smoke cannabis during pregnancy ‘double risk of stunting baby’s growth’ 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

Survey reveals risks, rewards of cannabis use

Some people with Parkinson’s disease find that using cannabis products helps to ease certain symptoms, according to results from a survey.

The findings notably suggest that cannabis products with high levels of the chemical THC are more likely to induce both positive and negative effects in Parkinson’s patients.

“These survey results offer a broad overview of real-world cannabis use patterns and experience among a large group of people living with [Parkinson’s] and provide initial results regarding the differential symptomatic effects of” different cannabis products, researchers wrote.

Findings were published in the study, “Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson’s disease,” in Movement Disorders.

 

Cannabis has two main active components: tetrahydrocannabinol (THC), which is the main chemical that induces a “high,” and cannabidiol (CBD), which doesn’t induce a “high” but may have numbing or anti-inflammatory properties.

e-mail icon
Continue reading

New Medical Cannabis Program goes into effect across the state

This expands the eligibility criteria for patients who can benefit from medical cannabis and makes it easier for them to be certified by a medical practitioner.

A new Medical Cannabis Program certification and registration system went into effect on Monday across the state. 

This expands the eligibility criteria for patients who can benefit from medical cannabis and makes it easier for them to be certified by a medical practitioner.

Last year's marijuana regulation and taxation act ensured that this new system will be run by the office of cannabis management instead of the health department.

“It is terrific to see the Medical Cannabis Program expand so vastly with the launch of the new certification and registration program and the ability of practitioners to determine qualifying conditions as included in the MRTA,” said Cannabis Control Board Chair Tremaine Wright. 
 
“The new cannabis industry is taking shape as we continue to implement the MRTA and provide greater access for New Yorkers to a medicine that we’re learning more about every day. We’re continuing to move forward swiftly and today’s system launch follows our achievements that already include adding whole flower medical product sales, permanently waiving $50 patient fees, and advancing home cultivation regulations, among others.”

The program was first proposed back in October.

Patients who are certified through the new certification and registration system will be issued a new certification from the New York State Office of Cannabis Management after the current one expires.

e-mail icon
Continue reading

Does cannabis cause psychosis? A new study sheds some light

Responsible parties should inform consumers, especially teens, about the harms of cannabis and the serious conditions that may arise from abusing the substance.

One of marijuana’s most concerning connections is the one it has with psychosis. While not wholly understood, this link has been reported to be significant, with several studies indicating that people who smoke large amounts of weed on a daily basis are five times more likely to develop psychosis than others. This depends on the age at which marijuana is first consumed and the individual’s genetic vulnerabilities.

Now, a new study provides some much-needed information and context on the topic.
 
Published in the American Journal of Psychiatry, the study looked into the connection between schizophrenia and cannabis and tried to provide answers to a question that has long been unanswered: Does cannabis use cause schizophrenia, or are people who suffer from schizophrenia more likely to seek out the drug?
 
The study looked into young subjects, all within the ages of 13 to 16, who filled out annual self-reports of past-year cannabis use and psychotic symptoms.
 
The findings spotted clear links between frequent cannabis use and more psychotic symptoms. Subjects who reported cannabis use in the previous year were more likely to experience psychotic symptoms a year afterward.
 
Still, the finding is not necessary foolproof evidence of causation. Many more studies need to be conducted to have a better understanding of the issue, and to know how to address it properly, especially in the case of children and teens, who are at higher risk for harm when exposing their young brains to cannabis.
 
While studies like this can be scary for cannabis proponents, they are necessary for having a thorough understanding of the plant.
 
As cannabis gets legalized across U.S. states, responsible parties should inform consumers, especially teens, about the harms of cannabis and the serious conditions that may arise from abusing the substance.
 
Most people can use cannabis safely. Still, that doesn’t mean everyone should turn a blind eye to those who are exposed to greater risks.
 
 
Rate this article: 
Select ratingGive Does cannabis cause psychosis? A new study sheds some light 1/5Give Does cannabis cause psychosis? A new study sheds some light 2/5Give Does cannabis cause psychosis? A new study sheds some light 3/5Give Does cannabis cause psychosis? A new study sheds some light 4/5Give Does cannabis cause psychosis? A new study sheds some light 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

4 things to know about Delta-8-THC, the new cannabis drug

 

New studies: Survey of user experience and warnings of unregulated contaminants.

The sudden appearance of delta-8-tetrahydrocannabinol (delta-8-THC, or delta-8) and its quick rise in popularity is a classic tale of unintended consequences and loopholes that enterprising entrepreneurs rush through.

 

1. Delta-8 is a cannabinoid molecule naturally found in cannabis.

The cannabis plant contains over 100 similar molecules called cannabinoids, most of them in small quantities and with unknown properties. Delta-9-tetrahydrocannabinol, commonly called THC, is the most abundant and most psychoactive molecule in popular strains of marijuana. When the double bond between two carbon atoms shifts location slightly, it creates delta-8, which has similar effects as delta-9 but is only two-thirds as strong. Until recently, delta-8 was little known because cannabis plants contain only .1 percent delta-8, which is too little to extract profitably.

2. Delta-8 is legal and unregulated.

The 2018 Farm Bill legalized industrial hemp products as long as the delta-9 content remained below .3 percent. This bill permitted a great increase in the production of CBD (cannabidiol), which exists in sufficient amounts in hemp to be extracted profitably. When over-production of CBD created a glut that plummeted prices in 2020, the industry began looking for innovative ways to make the excess CBD profitable. Simple chemistry discovered in the 1960s using solvents like toluene began being used to convert CBD into delta-8.

Since the Farm Bill said nothing specific about delta-8, it remained legal federally, and only 14 states have restricted its sale to date. Able to be offered on the Internet, mailed through the US Postal Service, and sold in gas stations, convenience stores, and cannabis dispensaries, it has been the fastest-growing segment of the hemp-derived market this last year, says Ian Laird of data analytics company Hemp Benchmarks.

e-mail icon
Continue reading

CBD for sleep: CBN competes with Ambien and Melatonin

The hemp industry has been unloading products containing new alternative cannabinoids targeting specific moods and providing more benefits. One of the cannabinoids increasing in popularity is called CBN (Cannabinol), also known as the CBD for sleep.

CBN is a cannabinoid found in, and derived from, the hemp plant. Although close in chemical structure to CBD, the compounds produce very different results. CBN is specifically for getting to sleep, staying asleep and for anti-anxiety.

What is CBN?

Cannabinol, the scientific name for CBN, has been the newest upcoming cannabinoid and consumers have been flocking to it due to its sleep and relaxing properties.

CBN is created naturally due to the degradation of Delta 9 THC. Because of the technology that hemp companies have been able to scale, this magical cannabinoid can now be adopted at scale by consumers.

What is the difference between CBN and CBD?

Due to the fact that the hemp industry is discovering more potent benefits the alternative cannabinoids are offering, CBD has been slowly fading out into the background due to its lack of strength in benefits compared to CBN and others.

e-mail icon
Continue reading

Medical cannabis expansion launches in Utah

An expansion to Utah's medical cannabis program has officially launched, allowing more health care workers to recommend marijuana to qualifying patients.

The program allows any licensed physician, physician's assistant, nurse or podiatrist with a controlled substance license to recommend cannabis to up to 15 patients. There are more than 21,000 medical providers who can now recommend medical cannabis, the Utah Department of Health said.

"This program expands access to medical cannabis for qualifying patients by increasing the number of clinicians who have the option to recommend medical cannabis. In the past, adult patients had to obtain a recommendation from one of the 800 medical providers who were registered with the Utah Department of Health but that is no longer the case," Richard Oborn, Utah Department of Health's Center for Medical Cannabis director, said in a statement.

FOX 13 first reported in 2019 about problems qualifying patients were having getting a physician willing to recommend. The Utah State Legislature created the "limited medical provider" option to get health care workers more comfortable with cannabis.

The expansion was supposed to launch last October, but staffing and technology issues delayed it. Lawmakers, caught off guard by the delay, were not pleased and demanded timelines be sped up. Patient advocates were also frustrated.

e-mail icon
Continue reading

Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center

Marijuana edibles are becoming increasingly popular, but doctors warn the substances are prone to accidental consumption or may pack too much of a wallop for new users.

Newly released numbers show marijuana overdose-related calls in Illinois jumped significantly after legalization, mainly due to edibles — but remained far below the number of calls for other legal drugs, including alcohol.

The number of calls to the Illinois Poison Center for cannabis rose from 487 in 2019, to 743 in 2020, the year recreational weed was legalized in the state, and increased again to 855 in 2021.

Many of the calls were for consumption of edibles, officials said. Edible cases more than tripled from 80 cases in 2019 to 450 in 2021.

“Looking at the reason for exposure, almost all were unintentional,” said Dr. Michael Wahl, medical director of the poison center.
 
“People didn’t mean to eat them, or didn’t know what they were eating.”
 
Most regular consumers of cannabis have a better idea of what to expect and don’t call the center, he said.

Many of the calls are for children. Calls to the poison center increased for children 5 and under from 81 in 2019, to 278 in 2021.

Some calls involve visitors, such as grandparents or babysitters, to a home where they came across edibles, Wahl said. About two-thirds of the calls came from health care facilities looking for advice on how to treat marijuana intoxication. Most cases were not severe and were resolved over the phone, but some required hospitalization until the effects wore off.
 
Symptoms of severe THC poisoning can include respiratory distress, loss of coordination, lethargy and loss of consciousness, or in milder cases, anxiety, paranoia and heart palpitations. The effects depend largely on the amount consumed compared to body weight, which is why children can have more severe reactions.
 
Edibles avoid the harmful effects on the lungs from smoking pot, but may have more variable amounts of THC, the main psychoactive component in cannabis, and may take an hour or two to fully kick in, prompting some impatient users to take too much. As a result, cannabis companies advocate starting with low doses and taking time to see their effects.
 
Despite the increases, the number of cannabis-related cases pales in comparison to the thousands of calls for other legal drugs such as pain killers, cleaning products, sedatives and antipsychotics, cosmetics, antidepressants and alcohol. Out of more than 80,000 calls to the poison center last year, 33,000 were for children under 5, so cannabis accounted for fewer than 1% of those calls.
 
Treatment often involves keeping the person calm and under observation, the center’s medical director said. All the cannabis patients fully recovered. Much bigger concerns, Wahl said, are drug interactions with alcohol, and the increase in fentanyl poisonings, including in counterfeit pills and in illegal cannabis.
 
No calls to the poison center involving cannabis have been fatal, but authorities warn that the drug may worsen the effects of other, potentially fatal substances.
 
Kevin Sabet, president of Smart Approaches to Marijuana, which opposes legalization, called the increase in cases an emergency.
 
“We need lawmakers to act now to restrict the potency of marijuana products,” he wrote in an email, “enact education campaigns on the dangerousness of today’s marijuana, and limit the influence of the marijuana industry in the state in general.”
 
The poison center doesn’t keep track of whether calls were for legal or illegal cannabis. But Pam Althoff, executive director of the Cannabis Business Association of Illinois, said unregulated cannabis products such as hemp-derived Delta-8-THC “weed light” and the highly potent THC-0 are more concerning than licensed, regulated cannabis, because consumers don’t know what they’re getting with such gray-market products sold in gas stations.
 
“I don’t see the need for more regulations (on legal edibles),” she said, “I see the need for more education.”
 
Despite the increase in cannabis use calls, another fear about legalization causing increased use among teens so far appears to have not panned out.
 
Adolescent cannabis use nationwide decreased significantly in 2021, according to the 2021 Monitoring the Future survey produced by the National Institute on Drug Abuse. The declines in teen drug use overall, thought to be related to restrictions prompted by the COVID pandemic, were the greatest since the survey began in 1975.
 
In addition, a prominent local treatment center for drug abuse, Rosecrance Health Network, has not seen a marked increase in long-term cannabis use disorder by itself, said Chief Medical Officer Dr. Tom Wright. 
 
“With adults, we’re noticing the trend that cannabis use tends to be combined with other substances, such as alcohol,” he said. “We do anticipate a growing need for cannabis treatment as use continues to become more common."
Rate this article: 
Select ratingGive Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center 1/5Give Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center 2/5Give Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center 3/5Give Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center 4/5Give Marijuana edibles spurring rise in pot-related overdose calls to Illinois Poison Center 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

WeedLife.com